Published in Hum Vaccin Immunother on January 01, 2015
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology (2010) 7.24
Papillomaviruses in the causation of human cancers - a brief historical account. Virology (2009) 5.46
Efficient intracellular assembly of papillomaviral vectors. J Virol (2004) 5.36
Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr (2003) 4.35
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14
Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis (1999) 4.05
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med (2005) 3.26
Maturation of papillomavirus capsids. J Virol (2005) 3.18
A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (2012) 3.03
Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ (2011) 2.95
A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31
Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol (1997) 2.29
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) (2013) 2.17
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine (2011) 1.91
Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine (2008) 1.75
In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids. J Virol (1998) 1.55
Infectious human papillomavirus type 18 pseudovirions. J Mol Biol (1998) 1.51
In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res (1998) 1.44
Assembly of human papillomavirus type 16 pseudovirions in Saccharomyces cerevisiae. Hum Gene Ther (2000) 1.34
Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis (2009) 1.29
Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol (1992) 1.24
In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol (1998) 1.20
Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro. J Invest Dermatol (1995) 1.14
A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol (2012) 1.13
Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda. Vaccine (2014) 1.05
Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®). Vaccine (2012) 0.97
Optimization of multimeric human papillomavirus L2 vaccines. PLoS One (2013) 0.95
High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One (2013) 0.93
Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. J Clin Microbiol (2002) 0.91
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Hum Vaccin Immunother (2013) 0.87
Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS One (2011) 0.83
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat Immunol (2004) 2.96
Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol (2002) 2.29
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) (2013) 2.17
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine (2011) 1.91
A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res (2010) 1.82
Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine (2008) 1.75
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev (2009) 1.70
Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst (2013) 1.59
Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res (2006) 1.59
Common genetic variants and risk for HPV persistence and progression to cervical cancer. PLoS One (2010) 1.43
Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation. J Immunol (2005) 1.42
Human papillomavirus vaccines--immune responses. Vaccine (2012) 1.40
Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer Epidemiol Biomarkers Prev (2010) 1.36
Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol (2005) 1.34
Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer (2010) 1.32
A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis (2011) 1.31
Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood (2006) 1.21
Drug user treatment referrals and entry among participants of a needle exchange program. Subst Use Misuse (2002) 1.19
The use of human papillomavirus seroepidemiology to inform vaccine policy. Sex Transm Dis (2009) 1.14
A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma. Blood (2013) 1.14
Direct comparison of HPV16 serological assays used to define HPV-naïve women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev (2012) 1.09
Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol Biomarkers Prev (2010) 1.06
Ribonuclease is partly responsible for the HIV-1 inhibitory effect activated by HLA alloantigen recognition. AIDS (2003) 1.06
Immune profiling of plasma and cervical secretions using recycling immunoaffinity chromatography. Cancer Epidemiol Biomarkers Prev (2003) 1.03
Determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infect Dis (2010) 1.03
Efficacy of cone-beam computed tomography during transcatheter arterial chemoembolization for hepatocellular carcinoma. Jpn J Radiol (2011) 1.03
Enhancement of display efficiency in yeast display system by vector engineering and gene disruption. Appl Microbiol Biotechnol (2009) 1.02
Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica. Sex Transm Dis (2010) 1.02
Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection. Cancer Epidemiol Biomarkers Prev (2010) 1.02
HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One (2013) 0.99
Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica. J Infect Dis (2013) 0.99
Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®). Vaccine (2012) 0.97
Evaluation of a novel PCR-based assay for detection and identification of Chlamydia trachomatis serovars in cervical specimens. J Clin Microbiol (2007) 0.95
Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine (2010) 0.94
Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients. J Immunol (2009) 0.93
Conformational switching in ezrin regulates morphological and cytoskeletal changes required for B cell chemotaxis. J Immunol (2011) 0.92
Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles. Clin Vaccine Immunol (2007) 0.92
Changes in willingness to participate in HIV vaccine trials among HIV-negative injection drug users. AIDS Behav (2005) 0.92
Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure. Sex Transm Dis (2011) 0.91
Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection. Cytokine (2010) 0.90
Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes (2012) 0.90
CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors. J Immunol (2004) 0.88
Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies. Clin Vaccine Immunol (2007) 0.87
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Hum Vaccin Immunother (2013) 0.87
Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infect Dis (2014) 0.87
Medical history and the risk of biliary tract cancers in Shanghai, China: implications for a role of inflammation. Cancer Causes Control (2011) 0.86
Role of DC-SIGN in the activation of dendritic cells by HPV-16 L1 virus-like particle vaccine. Eur J Immunol (2006) 0.85
DNAse treatment following thawing of cryopreserved PBMC is a procedure suitable for lymphocyte functional studies. J Immunol Methods (2006) 0.85
Anti-Müllerian hormone deficiency in females with Fanconi anemia. J Clin Endocrinol Metab (2014) 0.84
Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination. Am J Epidemiol (2014) 0.83
Cytokine production by bone marrow mononuclear cells in inherited bone marrow failure syndromes. Br J Haematol (2013) 0.83
Determinants and correlation of systemic and cervical concentrations of total IgA and IgG. Cancer Epidemiol Biomarkers Prev (2009) 0.83
Ezrin tunes the magnitude of humoral immunity. J Immunol (2013) 0.83
Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. Am J Epidemiol (2014) 0.82
Multiplex cytokine analysis technologies. Expert Rev Vaccines (2010) 0.81
Usefulness of C-arm CT during superselective infusion chemotherapy for advanced head and neck carcinoma. J Med Imaging Radiat Oncol (2011) 0.81
Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study. Int J Cancer (2013) 0.80
Alterations of T-cell surface markers in older women with persistent human papillomavirus infection. Int J Cancer (2011) 0.79
Reduced serum levels of anti-Müllerian hormone in females with inherited bone marrow failure syndromes. J Clin Endocrinol Metab (2014) 0.78
Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels. Front Oncol (2012) 0.78
Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus. Hum Vaccin Immunother (2014) 0.77
Portal blood supply to locally progressed hepatocellular carcinoma after transcatheter arterial chemoembolization: Observation on CT during arterial portography. Hepatol Res (2011) 0.77
Comparison of benchtop microplate beta counters with the traditional gamma counting method for measurement of chromium-51 release in cytotoxic assays. Clin Diagn Lab Immunol (2004) 0.77
Microcoil embolization during abdominal vascular interventions through microcatheters with a tip of 2 French or less. Jpn J Radiol (2011) 0.77
Angiographic evaluation of feeding arteries of hepatocellular carcinoma in the caudate lobe of the liver. Cardiovasc Intervent Radiol (2010) 0.76
ABC transporters and cell wall proteins involved in organic solvent tolerance in Saccharomyces cerevisiae. J Biotechnol (2013) 0.75
Sexual risk behavior among injection drug users before widespread availability of highly active antiretroviral therapy. AIDS Behav (2005) 0.75
Spectroscopic imaging as triage test for cervical disease. J Low Genit Tract Dis (2008) 0.75
Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. Hum Vaccin Immunother (2014) 0.75